October 04, 2005 12:59 ET

Nymox NXC-4720 Product in Late Stage Development for E. Coli O157:H7 Contamination

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Oct 4, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has developed NXC-4720, a new proprietary treatment of potentially fatal E. coli O157:H7 contamination. Laboratory studies showed that NXC-4720 is capable of reducing the level of E. coli O157 contamination on fresh beef by over 99%.

Many recent outbreaks of deadly E. coli O157:H7 contamination (for example, in Ireland and in the U.S. in the past month), have reinforced the urgent need for control of this dangerous food pathogen.

E. coli O157:H7 bacterial contamination of food, drink and water supplies is a major public health problem throughout the world and can cause severe bloody diarrhea and abdominal cramps, leading in some cases to kidney failure, particularly in young children and in the elderly, with often serious long term and sometimes fatal results.

Despite efforts to improve the safety of the U.S. food supply, outbreaks of potentially deadly E. coli O157 food contamination remain common. According to a study by researchers at the Centers for Disease Control (CDC), from 1982 to 2002, a total of 350 E. coli O157 outbreaks spanning 49 states were reported to the CDC. While ground beef was the most common source of outbreaks, other sources such as produce, dairy products, drinking water and animal contact were also significant. According to the study, E. coli O157 infection each year in the U.S. causes an estimated 73,480 illnesses, often with highly serious medical complications.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information